Oncothyreon Inc., of Seattle, said the underwriters of its recently completed $40 million public stock offering fully exercised their overallotment option, boosting the gross proceeds to $46 million. Net proceeds of $43 million will support Oncothyreon's Phase I and Phase II cancer pipeline.